IP Library Granted Patent US 10,888,366
Granted Patent B2
US 10,888,366 · App. 15/893,178 · Granted Jan 12, 2021

Cryogenic blunt dissection methods and devices

Inventor: John Allison (Los Altos, CA)
Assignee: Pacira CryoTech, Inc.
A61B18/02A61F7/00A61B2018/00023A61B2018/00321A61B2018/00434A61B2018/00452A61B2018/0262A61B2018/0293
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,366
App. No.
15/893,178
Granted
Jan 12, 2021
Kind
B2
Abstract

A point of incision is created within tissue, the tissue having a temporoparietal fascia-deep temporoparietal fascia layer (TPF-sDTF) beneath skin and a temporal branch of a target nerve extending along a portion of the TPF-sDTF, the point of incision being laterally displaced from the target nerve. A cryogenic probe having a distal tip extending from an elongated body is inserted into the point of incision. The TPF-sDTF is bluntly dissected using the cryogenic probe such that a treating portion of the cryogenic probe is directly adjacent to a first treatment portion of the target nerve. The cryogenic probe is activated to create a first treatment zone at the first treatment portion of the target nerve to cause a therapeutic effect.

Claims (48)

1. A method for cryogenically treating a nerve of a patient, the method comprising:

creating an access site within tissue laterally displaced from a nerve, the tissue comprising skin, a layer of soft tissue and a layer of resilient tissue,

inserting a cryogenic probe having a cryogenic treating portion and a blunt distal tip extending from an elongated body into the access site, wherein the cryogenic probe includes a supply tube extending within the elongated body from a proximal end of the elongated body to the cryogenic treating portion;

bluntly dissecting the layer of soft tissue using the cryogenic probe such that the cryogenic treating portion of the cryogenic probe is directly adjacent to the layer of resilient tissue;

advancing the cryogenic probe such that the elongated body of the cryogenic probe laterally traverses along the layer of resilient tissue to position the cryogenic treating portion at a location adjacent to the nerve; and

activating the cryogenic treating portion to generate a treatment zone at the location to cause a therapeutic effect in the nerve.

2. The method of claim 1 , wherein the elongated body and supply tube are configured to resiliently bend.

3. The method of claim 1 , further comprising deflecting the blunt distal tip of the cryogenic probe against the layer of resilient tissue.

4. The method of claim 1 , further comprising bending a portion of the elongated body of the cryogenic probe prior to inserting the cryogenic probe into the access site.

5. The method of claim 1 , wherein a portion of the elongated body is configured to self-align within the layer of soft tissue to be substantially parallel with the layer of resilient tissue as it laterally traverses along the layer of resilient tissue.

6. The method of claim 1 , wherein the layer of soft tissue is comprised of adipose tissue, subcutaneous tissue, and/or muscle.

7. The method of claim 1 , wherein the layer of resilient tissue is a fascia layer.

8. The method of claim 1 , wherein the layer of resilient tissue is cartilage, periosteum, or bone.

9. The method of claim 1 , wherein the tissue comprises muscle under the layer of resilient tissue and wherein the layer of resilient tissue comprises a tissue interface separating the muscle and the layer of soft tissue.

10. The method of claim 1 , further comprising repeatedly moving and activating the cryogenic treating portion of the cryogenic probe such that a plurality of treatment zones is created across the nerve adjacent to the layer of resilient tissue and wherein moving the cryogenic treating portion comprises linearly withdrawing or advancing the cryogenic probe along the layer of resilient tissue.

11. The method of claim 1 , wherein the nerve is the temporal branch of a facial nerve.

12. The method of claim 1 , wherein the layer of soft tissue is a layer of temporoparietal fascia (TPF).

13. The method of claim 1 , wherein the layer of resilient tissue is a layer of deep temporoparietal fascia (sDTF).

14. The method of claim 1 , wherein the nerve is a sensory nerve.

15. The method of claim 1 , wherein the nerve is a motor nerve.

16. The method of claim 15 , wherein the treatment zone is cooled to a temperature of below about −20 degrees C.

17. The method of claim 15 , wherein the treatment zone is cooled to a temperature of below about −100 degrees C.

18. A method for cryogenically treating a nerve of a patient, the method comprising:

creating an access site within tissue laterally displaced from a nerve, the tissue comprising skin, a layer of soft tissue layer and a layer of resilient tissue,

inserting a cryogenic probe having a cryogenic treating portion and a blunt distal tip extending from an elongated body into the access site, wherein the cryogenic probe includes a supply tube extending within the elongated body from a proximal end of the elongated body to the cryogenic treating portion;

bluntly dissecting the layer of soft tissue using the cryogenic probe such that the cryogenic treating portion of the cryogenic probe is directly adjacent to the layer of resilient tissue;

advancing the cryogenic probe such that the elongated body of the cryogenic probe laterally traverses along the layer of resilient tissue to position the cryogenic treating portion at a first location adjacent to the nerve;

activating the cryogenic treating portion to generate a first treatment zone at the first location to cause a therapeutic effect in the nerve; and

relocating the treating portion of the cryogenic probe to a second location

and activating the cryogenic treating portion to generate a second treatment zone at the second location to further the therapeutic effect.

19. The method of claim 18 , wherein the treating portion of the cryogenic

probe is relocated to the second location without withdrawing the treating portion from the access site.

20. The method of claim 18 , wherein the second treatment zone is adjacent to the first treatment zone.

21. The method of claim 18 , wherein the second treatment zone overlaps with the first treatment zone.

22. The method of claim 18 , wherein the treatment zones comprise a treatment fence across the nerve.

23. The method of claim 18 , wherein the treatment zones comprise a treatment plane across the nerve.

24. The method of claim 18 , wherein the treatment zones are spatially separated from each other.

25. The method of claim 18 , wherein the layer of soft tissue is comprised of adipose tissue, subcutaneous tissue, and/or muscle.

26. The method of claim 18 , wherein the layer of resilient tissue is a fascia layer.

27. The method of claim 18 , wherein the layer of resilient tissue is cartilage, periosteum, or bone.

28. The method of claim 18 , wherein the tissue comprises muscle under the layer of resilient tissue and wherein the layer of resilient tissue comprises a tissue interface separating the muscle and the layer of soft tissue.

29. The method of claim 18 , wherein the nerve is the temporal branch of a facial nerve.

30. The method of claim 18 , wherein the layer of soft tissue is a layer of temporoparietal fascia (TPF).

31. The method of claim 18 , wherein the layer of resilient tissue is a layer of deep temporoparietal fascia (sDTF).

32. The method of claim 18 , wherein the nerve is a sensory nerve.

33. The method of claim 18 , wherein the nerve is a motor nerve.

34. The method of claim 33 , wherein the treatment zone is cooled to a temperature of below about −20 degrees C.

35. The method of claim 33 , wherein the treatment zone is cooled to a temperature of below about −100 degrees C.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 31, 2023
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 063213/0864 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
SUPPLEMENTAL CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2021
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; FLEXION THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058516/0636 →
CONFIRMATORY ASSIGNMENT Recorded Jul 15, 2019
From: MYOSCIENCE, INC.
To: PACIRA CRYOTECH, INC.
Reel/Frame 049758/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2018
From: ALLISON, JOHN
To: MYOSCIENCE, INC.
Reel/Frame 047860/0213 →
Cited By (14)
US 1,108,456 US 12,433,657 US 12,458,424 US 12,458,530 US 12,471,977 US 12,484,950 US 12,514,748 US 12,551,258 US 12,551,259 US 12,558,257 US 12,611,375 US 12,667,483 US 12,697,247 US 12,708,422